

INDEX

- Acatalasemia, 84
Acetoacetyl-CoA deacylase, 208
Acetyl CoA synthetase, 205
Acetylphenylhydrazine, 225
Acetylsalicylic acid, 225
Aconitase, 80, 84
Acrodermatitis enteropathica, 292, 326–327
Actinomycin D, 268
Adenosine triphosphate (ATP), 159, 160
Adenyl cyclase, 59, 364
Adolescent nutritional dwarfism, *see*
Dwarfism, adolescent nutritional
Adrenochrome, 25
Adrenodoxin, 80
Alcohol, 97, 121, 138, 379
Alcohol withdrawal syndrome, 177
Alcoholism, chronic, 119, 121, 123, 125, 128, 172, 173, 177, 295, 313
Aldosterone, 315
Aldosteronism, 175
Alkaline phosphatase, 255–256, 259, 262, 296–297, 300
Aluminum, 129
Aluminum acetate, 12
Amine oxidases, 19, 22, 28
3-Amino-1,2,4-triazole (Aminotriazole), 379
 δ -Aminolevulinic acid dehydrase (ALA-D), 87, 364
 δ -Aminolevulinic acid synthetase (ALA-S), 86, 363
Ammonium chloride, 174
Anaerobe, obligate, 27
Anemia, 17, 18, 19, 35, 36
 aplastic, 93, 124
 cadmium and, 359
 of chronic blood loss, 78, 95, 105, 217
 copper deficiency, 31, 37
 dimorphic, 111
 hemolytic, 93, 97, 125, 134, 219, 225
 hypochromic, microcytic, 78, 107
 refractory, with tumors and
 hyperglobulinemia, 114
 iron-deficiency, 90, 95, 105–114, 217
 congenital, 111–112
 nutritional, in infants, 107–108
 iron-loading, 102, 111, 116
 pernicious, 93, 111, 124
 phenylhydrazine-induced, 217
 pyridoxine-responsive, 115, 122
 sickle cell, 39, 257, 263, 316, 321–326
 sideroblastic, 115–125, 134
 acquired idiopathic, 117–118, 119, 124
 clinical features, 121–122
 course and prognosis, 124
 hereditary (sex-linked), 116–117
 pathology, 122–123
 treatment, 124
Aneurysms, 21
Angiorrhexis, 21
Antithyroid agents, 68
Aortic plaques, 10
Apatite, 56
Apoferitin, 79, 90, 127
Ascidians, 208
Ascorbate (ascorbic acid), 27, 192

- Ascorbic acid oxidase, 18
 Aspartate transcarbamylase, 255
 Ataxia, 17, 195, 196
 neonatal (swayback), 23, 24, 25
 Atherosclerosis, 210
 Athyreosis, 71
 Atransferrinemia, congenital, 111, 125
 Azathioprine, 113
- BAL, *see* British anti-lewisite
 "Bantu siderosis," *see* Hemosiderosis,
 African nutritional
 Batten's disease, 228
 Benzylamine oxidase, 28
 Bichromates, 12
 Biliary obstruction, 32
 Bone marrow, 31, 32, 38
 hyperplasia, 134
 Bordeaux mixture, 43
 Brainstem, 24
Brassica species goitrogenicity, 73
 Brewer's yeast, 5, 10, 11
 British anti-lewisite (BAL), 12, 238, 369,
 379
 Bromobenzene, 238
 Burn patient, 172, 316
- Carbimazole, 73
 Carbohydrate loading, 4
 Carbohydrate metabolism, manganese
 deficiency and, 197
 Carbon tetrachloride toxicity, 223
 Carbonic anhydrase, 253, 257
 Carboxypeptidases, pancreatic, 256–257,
 262
 Carcinoma, 34
 Catalase, 82, 84, 220
 Cataracts, 224–225
 Catecholamines, 24–25
 Cattle
 falling disease, 20
 salt sick, 17
 Celiac disease, 307
 Central nervous system disorders due to
 copper deficiency, 23–25
 Cerebrocuprein, 26
 Cerebrospinal fluid (CSF) magnesium in,
 173
- Ceruloplasmin, 19, 29, 32, 35, 36, 38
 effect on iron metabolism, 30, 97, 99
 Chloramphenicol, 118, 120, 121
 Chlorophyll, 159
 Chloroplast magnesium, 160
 Chlorosis, 77–78, 108
 Cholesterol, serum, 10, 24, 71
 Cholesterol synthesis, 192
 Chondrogenesis, 196
 Chromate, 5, 12
 Chromium, 3–12
 absorption, 5–6
 biochemistry, 4
 deficiency, 3, 4
 clinical effects, 8–9
 in diabetes, 6, 8
 dietary intake, 5, 8, 9
 in drinking water, 5
 glucose loading and, 7
 glucose tolerance factor (GTF)-bound, 6,
 7
 hair concentrations, 6, 7
 hepatic, 6, 8
 hexavalent, 12
 inorganic trivalent, 4, 6, 10, 11
 metabolism, 4–7
 placental transport, 7
 plasma levels, 6, 7
 tissue concentrations and age, 8, 10
 toxicity
 acute, 11–12
 chronic, 12
 treatment, 12
 Chronic alcoholism, *see* Alcoholism,
 chronic
 Chronic granulomatous disease (CGD),
 227–228
 Chronic renal failure, 174
 Cirrhosis, 32, 34, 175, 298
 Laennec's, 102, 125, 126, 128
 Collagen, 20, 21
 cross-linking and silicon, 209–210
 Collagen proline hydroxylase, 84
 Collagen synthesis, 364
 Colostrum, 66, 91, 251
 Copper, 17–44, 129
 absorption, 31–32
 added to animal feeds, 43
 biochemistry, 19–28

- Copper (*cont.*)
 in body tissues and fluids, 33–34
 deficiency, 17, 18, 37–39
 cardiac defects due to, 20–21
 central nervous system disorders due to, 23–25
 in infants, 18, 37–39
 iron metabolism defects due to, 18, 28–31, 38, 88, 92, 97
 skeletal defects due to, 20
 total parenteral nutrition-induced, 18, 39
 vascular defects due to, 21
 direct-acting, 35
 fungicide, 39, 40, 43–44
 ingestion and excretion, 32–33
 intrauterine contraceptive devices, 40, 43
 iron metabolism, role in, 28–31
 liver concentrations in disease, 34–35
 melanin formation and, 20
 metabolic pathways, 33
 metabolism, 31–37
 in milk during lactation, 36–37
 physiology, 19–28
 plasma, 20, 32, 35, 36
 toxicity, 39–44
 treatment, 42
 zinc antagonism and, 28, 278
 Copper sulfate, 38, 39
 Corticotropin, 271
 Cretinism, 71, 72
 Cross-link biosynthesis, 21
 Cross-linking, 18, 23
 of bone collagen, 20, 21
 of elastin, 20, 21
 silicon and, 210, 211
 role of zinc in, 278–279
 Cyanide, 83
 Cyanogenic glucosides, 73
 Cyclic adenosine monophosphate (Cyclic 3',5'-AMP), 195
 Cycloserine and sideroblastic anemia, 118, 120
 Cystic fibrosis, 36, 307
 Cystine metabolism, 279–281
 Cytochrome *c*, 81, 84
 Cytochrome oxidase, 18, 19, 24, 31, 35, 88
 Cytochrome P₄₅₀, 364
 Cytochromes, 79, 80, 82, 84
 Dehalogenase, 68
 Deiodinase, 68
 Deoxycorticosterone, 175
 Deoxyribonuclease, 205
 Desferoxamine, 132
 Desmosine, 22
 Diabetes
 chromium deficiency in, 6
 insulin-requiring, 6, 10–11
 mellitus, 126, 128, 132, 319
 Diabetic ketoacidosis, 174
 Dialysis and plasma zinc, 316
 Diamine oxidase, 28
 Diethylenetriaminepentaacetate (DPTA), 132, 368
 Digitalis toxicity, 174, 177
 3,4-Dihydroxyphenylalanine (dopa), 20, 195, 198
 3,4-Dihydroxyphenylethylamine (dopamine), 27, 195, 198
 3,5-Diiodo-3',5'-dibromothyronine, 69
 Diiodohydroxyquinolone, 327
 3,3'-Diiodothyronine, 69
 2,4-Dinitrophenol, 165
 Disaccharidase deficiency, 307
 Disulfide bonds, 25, 27
 Dithizone, 35
 Diuretic agents, 174
 DNA, 160, 205
 DNA-dependent RNA polymerase, 266
 DNA metabolism
 role of zinc, 255, 265, 278
 Dopa, *see* 3,4-Dihydroxyphenylalanine
 Dopamine, *see* 3,4-Dihydroxyphenylethylamine
 Dihydroxyphenylethylamine
 Dopamine- β -hydroxylase, 18, 27–28
 Dopaminergic system, 24
 Dwarfism
 adolescent nutritional, 306
 in iron and zinc deficiency, 109–110, 252, 305
 EDTA, *see* Ethylenediaminetetraacetate
 Elastin, 20, 21
 Enzootic neonatal ataxia, *see* Ataxia
 Epinephrine, 25
 Erythrocuprein, 26, 32, 35
 Erythrocytes, 36, 217–219
 Erythropoiesis, 31, 38, 93, 98, 103, 108

- Estradiol, 35
 Ethacrynic acid, 174
 Ethanol, *see* Alcohol
 Ethylenediaminetetraacetate (EDTA), 12, 368
 Extrapyramidal motor disease, 24, 198

 Fanconi syndrome, 41, 356
 Farnesyl pyrophosphate synthetase, 192
 Fasting, 97
 Fatty acid oxidase, 55
 Ferruginous micelle, 86
 Ferric citrate, 193
 Ferritin, 79, 80, 89–90, 91, 93, 127
 Ferrochelataase, 120, 121, 363, 364
 Ferredoxins, 80, 81
 Ferroprotoporphyrin, *see* Heme
 Ferroxidase (*see also* Ceruloplasmin), 29, 38, 99
 Folic acid, 124
 Folic acid deficiency, 110, 128
 Fluoride, 55–60
 absorption and distribution, 56
 biochemistry, 55–56
 body fluid concentrations, 56–57
 cariostatic effect, 55, 57, 58–60
 dietary, 56, 57
 in drinking water, 55, 57, 59
 inhibition of growth, 56
 metabolism, 56–57
 maternal transfer, 57–58
 in multiple myeloma, 57
 supplementation, clinical effects, 57–60
 toxicity, 60
 Fumarate, 27
 Furosemide, 174

 Galactocerebroside, 24
 Gastroferrin, 95, 127
 Geophagia (clay-eating), 108–109, 252, 293, 313
 Glanzmann's thrombasthenia, 221, 227
 Glucose loading (*see also* Carbohydrate loading), 7, 9
 Glucose tolerance, 3, 4, 7, 8, 9
 Glucose tolerance factor (GTF), 3, 4, 11
 activity of foods, 5
 serum insulin response, 9–10
 serum lipid levels and, 10
 Glucose tolerance test (GTT), 8, 9

 Glucose-6-phosphate dehydrogenase, 56, 218
 deficiency, 116, 117, 218
 Glutamic dehydrogenase, 259
 Glutathione peroxidase (GSH-Px)
 deficiency, 218, 220, 225, 227
 dependent peroxide decomposition, 218
 erythrocyte, 216, 217–219, 225
 in human diseases, 225
 iron deficiency anemia and, 217
 lens, 224–225
 liver, 222–224
 mechanisms, 221
 in phagocytic cells, 220
 plasma, 222
 red cell disorders, 225–227
 selenium and, 216
 Glutathione reductase deficiency, 218
 Glycolysis, 56, 81
 Glycosyl transferases, 191–192, 197
 Goiter, 63, 72
 cabbage, 73
 colloid, 72
 endemic, 63, 71, 74
 exophthalmic, 67, 69
 iodide, 74
 Goitrin (L-5-vinyl-2-thiooxalidone), 73
 Goitrogenic substances (goitrogens), 72–73
 Gonadotropin, 271
 Goodpasture's syndrome, 113–114
 Grave's disease, 67, 69
 Growth
 depression, 12, 109–110
 thyroid hormone and, 71
 Growth hormone, 300

 Hair metal analysis, 34, 298, 375
 in copper deficiency, 25
 Heme, 85
 Heme A, 19, 26
 Heme synthesis, 31, 85, 86–88, 118, 119–120, 121, 363, 367
 Hemochromatosis, 34, 36, 91, 93, 95, 102, 124, 125–139
 idiopathic, 125–133
 clinical features, 131–132
 etiology, 126
 inborn error of metabolism, 126–127
 laboratory data, 132–133
 pathogenesis, 127–129

- Hemochromatosis (*cont.*)
 idiopathic (*cont.*)
 pathology, 129–131
 treatment, 129, 133
 juvenile idiopathic, 133–134
 secondary, 134
 shunt, 135
 Hemocuprein, 19, 26
 Hemocyanin, 17
 Hemoglobin, 78, 79, 80, 81, 82, 85–86, 98
 concentrations, 88
 glutathione peroxidase (GSH-Px), 217
 synthesis, 18, 86
 Hemosiderin, 80, 89, 90, 91, 99, 103, 127,
 128, 129
 Hemosiderosis, 111–112, 114, 123, 125–139
 African nutritional, 138–139
 idiopathic pulmonary, 112–113
 Hepatitis, viral, 125, 134
 Hepatocuprein, 35
 Hepatolenticular degeneration, *see*
 Wilson's disease
 Hepatosplenomegaly, 252, 303
 Hermanski–Pudlak syndrome, 227
 Hexose monophosphate shunt, 218, 220,
 221
 Histidine, 89, 92
 Hodgkin's disease, 36
 Hookworm infestation and iron deficiency
 anemia, 105, 110
 Hydremia, 88, 105
 Hydrogen peroxide, 216, 217, 219
 Hyperalimentation and zinc deficiency, 307
 Hypercalcemia, 169, 175
 Hypercupremia, 36
 Hyperferremia, 111
 Hyperglycemia, 8
 Hyperinsulinemia, 8
 Hyperkeratosis, 251
 Hypermagnesemia, 169, 175, 180
 in infants, 181
 Hyperparathyroidism, 175
 Hypertension, cadmium-induced, 354–355
 Hyperthyroidism, 65, 67, 71, 72, 175
 Hyperzincemia, 328
 Hyperzincuria, and renal disease, 315
 Hypocalcemia, 173, 175, 177, 180
 Hypoceruloplasminemia, 29
 Hypocupremia, 36, 37, 107–108
 Hypoferremia, 18, 29, 107
 Hypogeusia, 308
 Hypoglycemia, 11
 Hypogonadism, in iron and zinc deficiency,
 109–110, 252, 303
 Hypokalemic metabolic alkalosis, 174
 Hypomagnesemia, 171, 174, 175, 176, 177
 cardiac symptoms, 177
 renal causes, 174
 Hypomyelination, 23, 24, 25
 Hypoparathyroidism, congenital, 175
 Hypophosphatemia, 169
 Hypopituitarism, idiopathic, 303
 Hyposideremia, 296
 Hypothermia, 181
 Hypothyroidism, 69, 71, 74, 175
 Hypoxia, 93, 97

 Infantile hypomagnesemia, 175
 Inflammatory diseases, 97, 98
 Insulin, 4, 7, 9, 269, 271
 Insulin-requiring diabetics, *see* Diabetes,
 insulin-requiring
 Intrauterine contraceptive device, copper
 containing, 40, 43
 Iodine, 63–74
 absorption, 66
 antithyroid agent, 73
 biochemistry, 64–66
 body concentrations, 64
 clearance, 67
 content of foods, 72
 deficiency and thyroid function, 71–74
 in drinking water, 72
 during pregnancy, 65
 excretion, 66
 metabolic pools, 66–68
 metabolism, 66–71
 in milk, 65–66
 requirements, 72
 serum, 65
 toxicity, 74
 Iron, 34, 77–138
 absorption, 91–95, 102, 105, 125
 in copper deficiency, 28–31, 38
 mechanisms, 93–95
 biochemistry, 79, 80–84
 body concentrations, 85
 deficiency, 84, 88, 93, 97, 103–114
 clinical syndromes, 106–125
 lead and, 364

- Iron (*cont.*)
- deficiency (*cont.*)
 - treatment, 106
 - without anemia, 106
 - zinc deficiency and, 103, 107, 109–110, 296
 - enzymes, 83
 - excretion, 95–96
 - metabolism, 85–99
 - role of copper in, 28–31
 - defects due to copper deficiency, 18, 38, 88, 97
 - in milk, 91
 - mobilization, 99
 - non-heme, 91, 94
 - overloading, 135
 - serum concentrations, 88
 - diurnal rhythm, 89
 - sources, 99–100
 - storage compounds, 89–91
 - toxicity, acute, 114
 - transport, 83, 89, 94, 96
 - turnover rate, 98
- Iron-binding capacity, total, 103
- Iron-deficiency anemia, *see* Anemia, iron deficiency
- Isodesmosine, 22
- Itai itai byo, 349, 350, 356–357, 359
- Jaundice, neonatal, 225, 226
- Kaschin–Beck disease, 125
- Kayser–Fleischer ring, 41, 42
- Ketoacidosis (*see also* Diabetic ketoacidosis), 173
- Krebs cycle, *see* Tricarboxylic acid cycle
- Kwashiorkor, 8, 34, 36, 174, 306–307
- Laccase, 18
- Lactic dehydrogenase, 259
- Laennec's cirrhosis, *see* Cirrhosis, Laennec's
- Lead, 129, 363–369
 - absorption, 364
 - biochemistry, 363–364
 - collagen synthesis and, 364
 - effect on heme synthesis, 121, 363
 - exposure in pregnancy, 367
 - iron deficiency and, 364
 - metabolism, 364–365
- Lead (*cont.*)
 - sources of exposure, 365–366
 - toxicity, 365–369
 - clinical features, 366–367
 - diagnosis, 367–368
 - treatment, 368–369
 - zinc levels and, 364
- Lead encephalopathy, 367
- Lechsucht, 17
- Leukemia, 36, 119
 - acute granulocytic, 117, 124
 - acute myelogenous, 118, 129
- Leukocytosis, 227
- Lichen planus, 40
- Lipase, 55
- Lipoamide dehydrogenase, 364
- Lipoproteins and selenium, 233
- Lung cancer, 12
- Luteinizing hormone (LH), 272
- Lymphocytes and zinc, 282–283
- Lysine, 22, 89, 92
- Lysyl oxidase, 18, 23, 28, 278
- Macrophages, 280
- Magnesium, 159–181
 - absorption, 162
 - in anesthesia, 181
 - antacids, 181
 - biochemistry, 159–161
 - bone and, 170
 - cerebrospinal fluid (CSF), 173
 - compartmental analysis, 168
 - conservation on a low-magnesium diet, 166–168
 - deficiency, 166, 169, 170–180
 - clinical manifestations, 171
 - diagnosis, 176
 - therapy, 178–179
 - depletion, 169
 - distribution, 161–162, 166–167, 168
 - eclampsia treatment, 180
 - equilibrium in bone, 168
 - excretion, 164–166
 - food concentrations, 162
 - homeostasis, 169
 - intake, 162
 - intestinal malabsorption, 172, 176
 - oxidative phosphorylation, role in, 160–161
 - parathyroid hormone and, 165, 169–170

- Magnesium** (*cont.*)
 photosynthesis, role in, 159–160
 physiology and metabolism, 161–170
 plasma clearance, 166–168
 secretion, 164, 165
 serum, 161
 tissue uptake, 166–168
 toxicity, 180
 transport mechanisms, 163
 turnover, 161–162, 167
 wastage, familial, 174
- Magnesium gluconate**, 181
- Malnutrition**, 8, 18, 37, 97, 128, 174
- Manganese**, 26, 92, 191–198
 absorption, 193
 biochemistry, 191–193
 chondrogenesis, role in, 196
 body distribution, 194
 cartilage mucopolysaccharide, 196
 in cholesterol synthesis, 192
 deficiency, 192, 196–197
 carbohydrate metabolism in, 197
 mucopolysaccharide metabolism in, 197
 pyruvate carboxylase, 193
 skeletal abnormalities, 196
 vitamin K deficient diet, 197
 glycosyl transferase, 191–192, 197
 homeostasis, 194–195
 iron absorption and, 194
 metabolism, 193–194
 biogenic amines and, 195–196
 genetic interaction, 195
 metal–enzyme complexes, 191
 metalloenzymes, 191, 192–193
 in polysaccharide synthesis, 192
 porphyrins, 194
 toxicity
 chronic, 195
 treatment, 198
- Maturity-onset diabetes**, *see* Diabetes
- Meconium plug syndrome**, 181
- Melanin formation**, 20
- Menke's kinky hair syndrome**, 18, 25, 38, 39
- Menstruation**, and iron loss, 102, 105
- Mercurialism**, 373, 374
- Mercury**, 371–380
 absorption, 372
 accumulation, 371
- Mercury** (*cont.*)
 air levels, 374
 biochemistry and metabolism, 372–373
 distribution, 374
 diuretics, 174
 fetotoxicity, 371
 inorganic, 371, 372
 organic, 371, 372
 placenta barrier to, 372
 prenatal and postnatal exposure to, 376–378
 selenium antagonism, 373, 378
 toxicity, 373–380
 factors affecting, 375–376
 species difference, 373
 treatment, 379–380
- Metallothionein (MT)**, 268–269, 350–351, 358
- Methimazole**, 73
- Methylmercury toxicity**, 374, 376–378
- Milk diet**, 108
- Molybdenum**, 23, 32, 34, 84, 129
- Monoamine oxidase (MAO)**, 18, 28, 35
- Mucopolysaccharide metabolism**, effect of manganese on, 196, 197
- Mucosal block theory of iron absorption**, 79, 93
- Multiple myeloma**, 57, 119
- Myelofibrosis**, 229
- Myocardial infarction**, 36
- Myoglobin**, 80, 98
- Myxedema**, 69, 119
- NADH dehydrogenase**, 80
- Naphthalene**, 224
- Neutropenia**, 38, 39
- Nephrosis**, 33, 36
- Nickel**, 203–206
 biological functions, 205
 deficiency, 203, 204
 dietary sources and requirements, 205–206
 role in RNA and DNA, 205
- Nickeloplasmin**, 206
- Nicotinic acid**, 4, 10
- Nitrofurantoin**, 225
- Norepinephrine**, 25, 27
- Normoblasts**, 31, 32, 86
- Nucleic acid**
 metabolism and zinc, 262–267
 synthesis, 160

- Oral contraceptives
 serum copper levels and, 36
 zinc and, 320–321
- Osteitis fibrosa cystica, 175
- Osteomalacia, 356, 358
- Osteoporosis, 57
- Oxidative phosphorylation, 160–161, 373
- Paget's disease, 57
- Pagophagia (ice-eating), 109
- Pallid* gene, 195, 196
- Paraamino-salicylates, 73
- Parakeratosis, 251, 319
- Parathyroid hormone, and magnesium, 165, 169–170
- Parkinson's disease, 24, 195
 manganese toxicity and, 198
- Patterson–Kelly syndrome, *see*
 Sideropenic dysphagia
- Penicillamine, 42, 238, 319, 368
- Perchlorate-type antithyroid agent, 68
- Pernicious anemia, *see* Anemia, pernicious
- Perosis, in chickens, 191, 193, 195, 196
- Peroxidases, 82
- pH, 30, 32
- Phagocytes, and GSH-Px, 220–221
- Phenacetin, and sideroblastic anemia, 118
- Phenylbutazone, 73
- Phosphoglucomutase, 205
- 6-Phosphogluconate dehydrogenase
 deficiency, 218
- Photosynthesis, 80–81, 159–160
- Phytate, 32, 92, 206, 292
- Pica, and iron deficiencies, 108–109
- Platelet metabolism, and GSH-Px, 221
- Plummer–Vinson syndrome, *see*
 Sideroblastic dysphagia
- Poliovirus, 284, 285
- Polynucleotide
 conformation, and zinc, 268
 synthesis, and zinc, 266
- Porphobilinogen (PBG), 87
- Porphyria, 125
- Porphyria cutanea tarda (PCT), 135–138
- Porphyrin, 17, 82
 magnesium chelate (chlorophyll), 159
 manganese-containing, 194
- Potassium chromate, lethal dose, 12
- Pregnancy
 iron deficiency in, 105, 109–110
 lead exposure in, 367
- Pregnancy (*cont.*)
 serum transferrin and, 97
 zinc and, 320–321
- Protoporphyrin IX, 88, 364
- Pseudomonas acidovorans*, 19
- Pseudomonas fluorescens*, 19
- Psoriasis, 317
- Pyrazinamide, and sideroblastic anemia,
 118
- Pyridoxal phosphate, 28, 121
- Pyridoxine, 42, 123–124, 353
 deficiency, 93
- Pyridoxine-free diet and sideroblastic
 anemia, 119
- Pyruvate carboxylase, 192, 193
- Renal iodide clearance, 67
- Respiratory decline, 223
- Respiratory paralysis, 180
- Rheumatoid arthritis, and anemia, 119
- Rhinovirus, 284, 285
- Rhopheocytosis, 111
- RNA, 205
- RNA-dependent DNA polymerase, 255
- RNA metabolism, role of zinc, 255
- Seborrheic dermatitis, treatment, 239
- Selenium, 215–240
 absorption, 231, 232
 antagonists, 230
 biochemistry, 215–225
 chemical form and availability, 229–230
 deficiency, 216, 219, 235–236
 cataracts resulting from, 224–225
 dental caries and, 238
 detoxification of cancer metabolites, 229
 diagnostic uses, 239–240
 dietary, 223, 229, 230
 distribution, 232–233
 excretion, 236
 food content, 230–232
 glutathione peroxidase, 215, 216
 homeostasis, 231
 medical applications, 239–240
 mercury antagonism, 373, 378
 metabolism, 229–234
 platelets and, 221–222
 teratogenic effects, 238
 tissue levels, 234
 toxicity, 232, 236–238
 treatment of, 238

- Serotonin, 25
 Serum cholesterol, *see* Cholesterol, serum
 Sickle cell anemia, *see* Anemia, sickle cell
 Sideroblastic dysphagia, 106–107, 296
 Siderophilin, *see* Transferrin
 Silica, cytotoxic effect, 280
 Silicon, 209–211
 biological functions, 209–210
 bone calcification, 209, 210
 cross-linking agent, 209–210
 deficiency, 210
 growth and, 210
 requirements, 210–211
 Silver, 230
 Sleep deprivation, 89
 Sodium retention, 354
 Spermine oxidase, 28
 Spices, chromium concentration, 4
 Squalene, 208
 Starvation, 173, 295, 316
 Succinate dehydrogenase, 80, 84
 Sulfisoxazole, 225
 Superoxide dismutase, 25, 26, 220
 Swayback, *see* Ataxia, neonatal

 T₃, *see* Triiodothyronine
 T₄, *see* Thyroxine
 Thalassemia, 34, 120, 125, 134
 Thiazide diuretics, 174
 Thiocyanate-type antithyroid agent, 68, 73
 Thioglycosides, 73
 Thionein, *see* Metallothionein
 Thiouracil-type antithyroid agent, 68, 73
 Thymidine, 263, 265
 Thymidine kinase, 255, 262, 265
 Thyroid gland, 63, 64, 67
 function in iodine deficiency, 71–74
 Thyroid hormones (*see also* Thyroxine, Triiodothyronine), 66, 68
 calorigenic action, 71
 effect on mitochondria, 69
 growth and, 71
 mechanisms of action, 69
 structural formulas, 70
 synthesis, 67–68
 Thyroid stimulating hormone (TSH), 66, 73
 Thyrotoxicosis, 73, 74
 Throtropin-releasing factor (TRF), 66
 Thyroxine, 63, 66, 68
 Tin, 211
 Total parenteral nutrition (TPN), 9, 18, 39, 319

 Transferrin, 6, 30, 80, 86, 96, 97, 99, 103, 363
 Tricarboxylic acid cycle, 82, 95
 Tri-*o*-cresyl phosphate, 230
 Tryptophan-2,3-dioxygenase, 19
 Tryptophan pyrrolase, 82–83
 Tuberculosis, 34
 Tyrosinase, 18, 20
 Tyrosine, 20, 68
 Tyrosine hydroxylase, 25

 Uric acid, 27
 Uricase, 18, 27

 Vanadium, 206–209
 biological functions, 207–208
 bone formation, 208
 deficiency, 207
 effect on cholesterol metabolism, 208
 requirements, 208–209
 sources, 208
 toxicity, 208
 Versenate (Calcium disodium edetate), 198, 368
 L-5-Vinyl-2-thiooxalidone, *see* Goitrin
 Vitamin A, 308
 Vitamin E, 216, 222, 223
 Vitamin K, 197

 Wilson's disease, 30, 32, 35, 36, 40–42, 319

 Xanthine oxidase, 80, 82, 84, 90, 99, 127
 Xanthine oxidation, 26–27

 Zinc, 18, 26, 32, 34, 39, 92, 251–329
 absorption, 289–292
 acrodermatitis and, 326–327
 alkaline phosphatase activity, 255–256, 296–297, 300
 availability, 292–293
 biochemistry, 253–285
 calcium and, 293
 collagen metabolism and, 272–279
 cysteine metabolism and, 279–281
 deficiency, 251, 252, 253, 254, 255, 256, 296–327
 in children and infants, 306–310
 collagen diseases and, 319–320
 congenital thymus hypoplasia, 328
 diagnosis, 310–312
 glucose tolerance and, 270

Zinc (*cont.*)deficiency (*cont.*)

- gonadal function, role in, 272
 - iron deficiency and, 103, 107, 109–110
 - parasitic diseases and, 318–319
 - prediabetic condition, 271
 - skin disorders and, 316–317
- distribution, 285
- effect on fibroblast proliferation, 277
- effect on protein synthesis, 275, 277
- excretion, 294–296, 311
- hormones, 269–272
- in human milk, 291
- intake, 294–296
- leukocytes, 288–289
- lymphocytes, 282–283

- metalloenzymes, 253, 254, 255, 258
 - metallothionein, 268–269
 - nucleic acid and, 262–267, 275
 - oral contraceptives, 320–321
 - pancreatic carboxypeptidases, 256–257
 - physiology, 253–285
 - plasma, 285–289
 - polynucleotide conformation and, 268
 - pregnancy and, 320–321
 - in red cells, 257, 283–284
 - replacement by lead, 364
 - sickle cell anemia and, 321–326
 - toxicity, 328–329
 - wound healing and, 277, 278, 317–318
- Zinc–copper antagonism, 34, 278
- Zinc–thionein synthesis, 268